Arcus Biosciences, Inc. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/d066746a-5ccd-4a91-9edc-b7b77ae5ff25/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $247.0M | 2025-01-01 – 2025-12-31 | evidence 0001724521-26-000009 |
| FY 2024 | $258.0M | 2024-01-01 – 2024-12-31 | evidence 0001724521-25-000040 |
| FY 2023 | $37.0M | 2023-01-01 – 2023-12-31 | evidence 0001724521-25-000040 |
| FY 2022 | $38.0M | 2022-01-01 – 2022-12-31 | evidence 0001724521-25-000040 |
| FY 2021 | $383.0M | 2021-01-01 – 2021-12-31 | evidence 0000950170-23-005112 |
| FY 2020 | $78.0M | 2020-01-01 – 2020-12-31 | evidence 0000950170-23-005112 |
| FY 2019 | $15.0M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-008972 |
| FY 2018 | $8.4M | 2018-01-01 – 2018-12-31 | evidence 0001564590-21-008270 |
| FY 2017 | $1.4M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-006274 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Arcus Biosciences, Inc. — all facts · Net Income · Operating Income